Kiromic Biopharma Stock Shares Owned By Institutions
| KRBPDelisted Stock | USD 2.68 0.07 2.55% |
Kiromic Biopharma fundamentals help investors to digest information that contributes to Kiromic Biopharma's financial success or failures. It also enables traders to predict the movement of Kiromic Stock. The fundamental analysis module provides a way to measure Kiromic Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiromic Biopharma stock.
Kiromic |
Kiromic Biopharma Company Shares Owned By Institutions Analysis
Kiromic Biopharma's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Kiromic Biopharma Shares Owned By Institutions | 68.00 % |
Most of Kiromic Biopharma's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiromic Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 68% of Kiromic Biopharma are shares owned by institutions. This is 52.33% higher than that of the Biotechnology sector and 43.16% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 73.43% lower than that of the firm.
Kiromic Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiromic Biopharma's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiromic Biopharma could also be used in its relative valuation, which is a method of valuing Kiromic Biopharma by comparing valuation metrics of similar companies.Kiromic Biopharma is currently under evaluation in shares owned by institutions category among its peers.
Kiromic Fundamentals
| Return On Equity | -11.3 | ||||
| Return On Asset | -0.92 | ||||
| Current Valuation | 9.55 M | ||||
| Shares Outstanding | 1.18 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 68.00 % | ||||
| Number Of Shares Shorted | 45.74 K | ||||
| Price To Book | 15.11 X | ||||
| EBITDA | (29.44 M) | ||||
| Net Income | (34.73 M) | ||||
| Cash And Equivalents | 6.51 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 9.41 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 1.35 X | ||||
| Book Value Per Share | (5.35) X | ||||
| Cash Flow From Operations | (23.75 M) | ||||
| Short Ratio | 0.93 X | ||||
| Earnings Per Share | (39.68) X | ||||
| Number Of Employees | 31 | ||||
| Beta | 0.16 | ||||
| Market Capitalization | 2.15 M | ||||
| Total Asset | 11.97 M | ||||
| Retained Earnings | (101.95 M) | ||||
| Working Capital | (11.59 M) | ||||
| Z Score | -21.07 | ||||
| Net Asset | 11.97 M |
About Kiromic Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kiromic Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiromic Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiromic Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Kiromic Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Kiromic Stock
Moving against Kiromic Stock
| 0.71 | MESO | Mesoblast | PairCorr |
| 0.65 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.46 | MDXG | MiMedx Group | PairCorr |
| 0.46 | VAXX | Vaxxinity | PairCorr |
| 0.4 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Kiromic Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiromic Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiromic Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiromic Biopharma to buy it.
The correlation of Kiromic Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiromic Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiromic Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiromic Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |